Yann Jamin
Overview
Explore the profile of Yann Jamin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
2111
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ferguson K, Gillen S, Chaytor L, Poon E, Marcos D, Gomez R, et al.
Dev Cell
. 2023 Sep;
58(19):1967-1982.e8.
PMID: 37734383
Neuroblastoma is the most common extracranial solid tumor in infants, arising from developmentally stalled neural crest-derived cells. Driving tumor differentiation is a promising therapeutic approach for this devastating disease. Here,...
2.
Reeves E, Li J, Zormpas-Petridis K, Boult J, Sullivan J, Cummings C, et al.
Mol Oncol
. 2023 Apr;
17(6):1076-1092.
PMID: 37081807
Hyaluronan (HA) is a key component of the dense extracellular matrix in breast cancer, and its accumulation is associated with poor prognosis and metastasis. Pegvorhyaluronidase alfa (PEGPH20) enzymatically degrades HA...
3.
King D, Li X, Almeida G, Kwok C, Gravells P, Harrison D, et al.
Oncotarget
. 2023 Jan;
14:21-22.
PMID: 36634205
No abstract available.
4.
Tucker E, Jimenez I, Chen L, Bellini A, Gorrini C, Calton E, et al.
Clin Cancer Res
. 2023 Jan;
29(7):1317-1331.
PMID: 36602782
Purpose: ALK-activating mutations are identified in approximately 10% of newly diagnosed neuroblastomas and ALK amplifications in a further 1%-2% of cases. Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) inhibitor, will...
5.
Parasaram V, Civale J, Bamber J, Robinson S, Jamin Y, Harris E
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230755
Preclinical investigation of the biomechanical properties of tissues and their treatment-induced changes are essential to support drug-discovery, clinical translation of biomarkers of treatment response, and studies of mechanobiology. Here we...
6.
Nijhuis A, Sikka A, Yogev O, Herendi L, Balcells C, Ma Y, et al.
Nat Commun
. 2022 Mar;
13(1):1380.
PMID: 35296644
Neuroblastoma is the most common paediatric solid tumour and prognosis remains poor for high-risk cases despite the use of multimodal treatment. Analysis of public drug sensitivity data showed neuroblastoma lines...
7.
Zormpas-Petridis K, Tunariu N, Curcean A, Messiou C, Curcean S, Collins D, et al.
Radiol Artif Intell
. 2021 Oct;
3(5):e200279.
PMID: 34617028
Purpose: To use deep learning to improve the image quality of subsampled images (number of acquisitions = 1 [NOA]) to reduce whole-body diffusion-weighted MRI (WBDWI) acquisition times. Materials And Methods:...
8.
Dubiella C, Pinch B, Koikawa K, Zaidman D, Poon E, Manz T, et al.
Nat Chem Biol
. 2021 May;
17(9):954-963.
PMID: 33972797
The peptidyl-prolyl isomerase, Pin1, is exploited in cancer to activate oncogenes and inactivate tumor suppressors. However, despite considerable efforts, Pin1 has remained an elusive drug target. Here, we screened an...
9.
Roeschert I, Poon E, Henssen A, Dorado Garcia H, Gatti M, Giansanti C, et al.
Nat Cancer
. 2021 Mar;
2(3):312-326.
PMID: 33768209
Amplification of is the driving oncogene in a subset of high-risk neuroblastoma. The MYCN protein and the Aurora-A kinase form a complex during S phase that stabilizes MYCN. Here we...
10.
Zormpas-Petridis K, Noguera R, Ivankovic D, Roxanis I, Jamin Y, Yuan Y
Front Oncol
. 2021 Feb;
10:586292.
PMID: 33552964
High computational cost associated with digital pathology image analysis approaches is a challenge towards their translation in routine pathology clinic. Here, we propose a computationally efficient framework (SuperHistopath), designed to...